{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1232","value":"4.218"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"389"}],"units":"Participants"}],"title":"Cycle 1 (day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"102","value":"18.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"267"}],"units":"Participants"}],"title":"Cycle 1 (day 15)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"96","value":"21.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"}],"units":"Participants"}],"title":"Cycle 1 (day 29)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"92","value":"24.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"314"}],"units":"Participants"}],"title":"Cycle 2 (day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"113","value":"22.62"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"}],"units":"Participants"}],"title":"Cycle 2 (day 29)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"98","value":"26.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"}],"units":"Participants"}],"title":"Cycle 3 (day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"82","value":"30.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"}],"units":"Participants"}],"title":"Cycle 3 (day 29)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"98","value":"29.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"}],"units":"Participants"}],"title":"Cycle 4 (day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"86","value":"31.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"}],"units":"Participants"}],"title":"Cycle 4 (day 29)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58","value":"39.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"}],"units":"Participants"}],"title":"Cycle 6 (day 1)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"389"}],"units":"Participants"}],"description":"Predose concentration during multiple dosing.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Avelumab PK concentration analysis set: all participants who had at least one post-dose concentration above lower limit of quantitation (LLQ) for avelumab. Here \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. \"Number Analyzed\" signifies number of participants evaluable for the specified rows. This outcome measure was not planned to be analyzed in ''Sunitinib'' reporting group.","reportingStatus":"POSTED","timeFrame":"Pre dose (0 hour) on Day 1, 15 and 29 of Cycle 1, Day 1 and 29 of Cycles 2, 3, 4 and Day 1 of Cycle 6","title":"Trough Plasma Concentration (Ctrough) of Avelumab","type":"SECONDARY","unitOfMeasure":"Micrograms per milliliter"}